TRUSELTIQ Drug Patent Profile

Which patents cover Truseltiq, and what generic alternatives are available?

Truseltiq is a drug marketed by Helsinn Hlthcare and is included in one NDA. There are four patents protecting this drug.

This drug has one hundred and thirty-six patent family members in forty countries.

The generic ingredient in TRUSELTIQ is infigratinib phosphate. Additional details are available on the infigratinib phosphate profile page.

DrugPatentWatch^® Generic Entry Outlook for Truseltiq

Truseltiq was eligible for patent challenges on May 28, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 11, 2034. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TRUSELTIQ

International Patents:	136
US Patents:	4
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	33
Clinical Trials:	2
Patent Applications:	75
Drug Prices:	Drug price information for TRUSELTIQ
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRUSELTIQ
What excipients (inactive ingredients) are in TRUSELTIQ?	TRUSELTIQ excipients list
DailyMed Link:	TRUSELTIQ at DailyMed

See drug prices for TRUSELTIQ

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TRUSELTIQ

Constraining patent/regulatory exclusivity:

10,278,969

NDA:

214622

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TRUSELTIQ

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Emory University	Phase 2
National Cancer Institute (NCI)	Phase 2
United States Department of Defense	Phase 2

See all TRUSELTIQ clinical trials

US Patents and Regulatory Information for TRUSELTIQ

TRUSELTIQ is protected by four US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 10,278,969.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Helsinn Hlthcare	TRUSELTIQ	infigratinib phosphate	CAPSULE;ORAL	214622-001	May 28, 2021		DISCN	Yes	No	10,278,969		Y
Helsinn Hlthcare	TRUSELTIQ	infigratinib phosphate	CAPSULE;ORAL	214622-002	May 28, 2021		DISCN	Yes	No	10,278,969		Y
Helsinn Hlthcare	TRUSELTIQ	infigratinib phosphate	CAPSULE;ORAL	214622-001	May 28, 2021		DISCN	Yes	No	11,160,804		Y
Helsinn Hlthcare	TRUSELTIQ	infigratinib phosphate	CAPSULE;ORAL	214622-002	May 28, 2021		DISCN	Yes	No
Helsinn Hlthcare	TRUSELTIQ	infigratinib phosphate	CAPSULE;ORAL	214622-002	May 28, 2021		DISCN	Yes	No	8,552,002		Y	Y

International Patents for TRUSELTIQ

When does loss-of-exclusivity occur for TRUSELTIQ?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Canada

Chile

China

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Morocco

New Zealand

Peru

Philippines

Poland

Portugal

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRUSELTIQ around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	098716
Australia	2014362999
Canada	2930055
Chile	2016001436
China	105813635

TRUSELTIQ (fostemsavir) market dynamics and financial trajectory: pricing, volume drivers, exclusivity cliffs, and revenue exposure

Last updated: July 10, 2026

TRUSELTIQ is the brand name for fostemsavir, an HIV-1 attachment inhibitor (sparing entry mechanism via gp120 binding). Market dynamics are dominated by (1) where fostemsavir is positioned in treatment guidelines for heavily treatment-experienced (HTE) patients with multidrug resistance, (2) payor access and site-of-care contracting, and (3) the timing of generic or biosimilar-free competitive pressure, since fostemsavir is a small-molecule single-ingredient product with typical small-molecule patent exclusivity mechanics rather than biologic switching.

What is TRUSELTIQ (fostemsavir) and where does it sit in HIV treatment markets?

TRUSELTIQ (fostemsavir) is an oral antiretroviral used in people with HIV-1 who have multidrug-resistance or cannot construct a suppressive regimen from existing options. Commercially, its demand is not driven by broad first-line use; it is driven by a narrow HTE population and by prescriber behavior in salvage settings.

Which patient segment drives TRUSELTIQ utilization?

• Heavily treatment-experienced adults with limited regimen options.
• Patients with resistance patterns that make at least two or more active drugs difficult to assemble.
• Use often concentrated in specialty care, including infectious disease clinics and hospital outpatient programs.

Why does salvage positioning matter for market growth?

Salvage therapies generally exhibit:

• Lower absolute addressable population than first-line regimens.
• Higher payer scrutiny per patient (authorization, resistance testing requirements, and step-therapy rules).
• Slower onboarding but stronger unit economics per patient once access is secured.

Key commercial implication

TRUSELTIQ revenue is expected to be relatively resilient to general HIV regimen cycles, but sensitive to:

• Changes in HTE sequencing guidelines
• Access restrictions and formulary placement
• The availability of alternative high-resistance-robust regimens (newer agents and fixed-dose combinations) that can reduce the need for attachment inhibition after failure.

How do pricing and reimbursement dynamics shape TRUSELTIQ revenue?

TRUSELTIQ pricing dynamics follow standard branded specialty drug patterns: launch-era price establishment, then payer-by-payer contracting based on patient-level clinical evidence, resistance constraints, and comparable alternatives.

What drives net price versus list price?

Net price for HIV specialty brands typically depends on:

• Medicare Part D and commercial PBM rebates
• Institutional contracting through IDNs, specialty pharmacy networks, and hospital outpatient formularies
• Prior authorization frequency and approval rates in high-resistance subgroups
• Discounting and co-pay assistance program structure (where permitted)

Market access “rate-limiting steps”

For attachment inhibitors in salvage:

• Payers often require documentation of treatment history and resistance testing.
• Coverage criteria may require failure of multiple prior classes.
• Authorization decisions can delay treatment initiation and shift dosing seasonality.

Financial trajectory impact

These access factors create a revenue curve with:

• Gradual adoption until payer coverage stabilizes
• Revenue pull-through in specific quarters when formulary wins or payer policy changes occur
• Higher volatility tied to reimbursement policy, not just clinical demand

What does competition look like for TRUSELTIQ in heavily treatment-experienced HIV?

TRUSELTIQ competes in salvage and multidrug resistance settings rather than mainstream first-line markets. Competitive pressure comes from any regimen that can achieve suppression where multidrug resistance is a barrier.

Which competitive categories most affect TRUSELTIQ uptake?

• Newer agents with resistance coverage that reduce attachment-inhibitor reliance
• Multi-class salvage strategies that improve regimen construction in HTE populations
• Once-daily and fixed-dose combinations that simplify adherence and clinic workflows

Switching dynamics

Switching pressure is typically payer-assisted rather than purely physician-driven:

• If a preferred alternative is covered with fewer authorization steps, uptake can move quickly.
• If multiple options are covered similarly, clinical fit and resistance profile dominate.

Commercial implication

TRUSELTIQ’s market share is constrained less by “same mechanism” competition and more by “regimen construction” alternatives that solve the prescriber’s salvage problem.

How does TRUSELTIQ adoption typically scale in a niche HIV indication?

Specialty niche brands often show adoption curves shaped by:

• Center-of-excellence prescribing patterns
• Specialist awareness and comfort with resistance testing workflows
• Pharmacy channel readiness, including specialty distribution and prior auth automation

Adoption drivers

• Resistance profile that makes fostemsavir a rational option
• Physician confidence built through clinical familiarity
• Patient adherence feasibility (oral dosing, tolerability management)

Adoption constraints

• Patient identification and resistance documentation requirements
• Insurance criteria that narrow eligible subpopulations
• Competing regimen preference after new therapy introductions

When does TRUSELTIQ face exclusivity cliffs, and how could generic entry affect financials?

This section requires specific TRUSELTIQ patent expiration, regulatory exclusivity dates, and Orange Book listings. Without those data for TRUSELTIQ in the U.S., the exclusivity and generic-entry timing cannot be stated accurately.

What is the FDA regulatory status of TRUSELTIQ, and how does that affect revenue duration?

Regulatory status determines label breadth, willingness-to-prescribe, and competition windows. Without the specific FDA approvals and labeling details for TRUSELTIQ, an exact revenue-duration mapping cannot be produced.

How strong is the TRUSELTIQ patent estate, and what litigation or settlement outcomes matter?

A credible revenue-impact assessment depends on:

• Patent numbers and expiration dates
• Whether key patents are method-of-use, formulation, or polymorph-related
• Whether Paragraph IV challenges or settlement agreements exist
• Whether any decision-making affects entry timing

This requires the TRUSELTIQ U.S. patent and Orange Book record, plus litigation docket data. Without that, the risk matrix for generic entry and the financial trajectory cannot be constructed.

What generic entry risks exist for TRUSELTIQ?

Generic-entry risk for a small-molecule HIV therapy typically includes:

• Launch with partial label carve-outs if only some patents are invalidated
• Entry contingent on design-around (new salt/polymorph/formulation)
• Pediatric exclusivity or other exclusivity layers that delay full commercialization

This risk cannot be quantified for TRUSELTIQ without Orange Book patent mappings and exclusivity periods.

How does TRUSELTIQ compare with other salvage HIV therapies on likely revenue exposure?

TRUSELTIQ revenue exposure depends on its share of:

• The HTE population with multidrug resistance
• Patient persistence on therapy
• Unit conversions from incident HTE patients and switching rates from alternative regimens

Without TRUSELTIQ sales history and without comparable competitor unit trends, a quantitative comparison is not possible.

What are the most likely financial trajectory scenarios for TRUSELTIQ (base, upside, downside)?

A scenario framework requires actual baseline revenue, market share, and pricing. Without TRUSELTIQ financial data, only directional qualitative drivers can be stated, which would not meet high-stakes business needs.

Base case drivers

• Stable HTE population identification and resistance testing access
• Continued specialty prescribing
• Gradual competitive pressure from salvage alternatives

Upside case drivers

• Expanded label use within allowable indications
• Payer policy easing (faster prior authorization, wider formulary inclusion)
• Lower real-world switching out due to regimen fit

Downside case drivers

• Increased payer restrictions tied to authorization criteria
• Preferred coverage shift to competing salvage regimens
• Faster substitution where new alternatives demonstrate strong resistance coverage

Key Takeaways

• TRUSELTIQ demand is structurally tied to HIV salvage treatment where multidrug resistance and regimen construction constraints prevail.
• Revenue dynamics are primarily driven by payor access mechanics, specialty prescribing patterns, and competition that improves the ability to assemble suppressive regimens in HTE settings.
• A reliable exclusivity and generic-entry-driven forecast requires TRUSELTIQ-specific Orange Book listings, patent expiration dates, and any Paragraph IV or settlement data. Without those records, an exclusivity cliff and revenue risk quantification cannot be provided.
• Near-term financial trajectory is most sensitive to net price changes from contracting and the authorization approval-rate impact of formulary and policy changes.

FAQs

1) Is TRUSELTIQ primarily sold through specialty pharmacies or hospital channels?

TRUSELTIQ is typically dispensed through specialty pharmacy networks and certain hospital outpatient channels consistent with HIV specialty prescribing and prior authorization workflows.

2) What payer criteria most often determine access to TRUSELTIQ?

Coverage is commonly gated by evidence of HTE status, treatment history documentation, and resistance testing requirements tied to salvage eligibility.

3) Does TRUSELTIQ compete more on mechanism or on regimen-building outcomes?

In salvage, it competes primarily on regimen-building outcomes in multidrug resistance contexts rather than on same-mechanism adjacency.

4) What factors influence persistence and adherence for TRUSELTIQ patients?

Tolerability management, oral dosing convenience, and clinic-supported adherence interventions influence persistence more than route-of-administration logistics.

5) How should investors assess TRUSELTIQ revenue risk without access to sales forecasts?

Focus on payer policy signals (formulary status and authorization criteria), specialty channel contracting changes, and the launch/take-rate pace of competing salvage regimens that reduce reliance on attachment inhibitors.

References

1. (Sources not provided in the prompt.)

DrugChatter Q&A for TRUSELTIQ

Can Truseltiq treat FGFR2-positive cancer?
Is truseltiq effective for fgfr2 fusions?
What are the side effects of truseltiq?
What is the dosing for truseltiq?